BioXcel Therapeutics Secures $8M, Extends Warrants with $1.614 Exercise Price
BioXcel Therapeutics closed a registered direct offering of 4,500,785 shares with accompanying warrants at $1.739 per unit, generating approximately $8.0 million in gross proceeds. The company lowered the exercise price of existing warrants to $1.614, extended their term to five years, and received $173,000 for the repricing.
1. Offering Details
On March 11, 2026, BioXcel Therapeutics closed its registered direct offering of 4,500,785 common shares and accompanying warrants at a combined price of $1.739 per unit, resulting in approximately $8.0 million in gross proceeds before placement agent fees and expenses.
2. Warrant Repricing and Extensions
The company reduced the exercise price of warrants covering 1,385,083 shares to $1.614 per share and extended their expiration to five years from closing, with the investor paying $173,000 for the repricing adjustment.